

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT5071601

|   |                              |                       |
|---|------------------------------|-----------------------|
| <b>SUBMISSION TYPE:</b>   | NEW ASSIGNMENT               |                       |
| <b>NATURE OF CONVEYANCE:</b>  | ASSIGNMENT                   |                       |
| <b>CONVEYING PARTY DATA</b>   |                              |                       |
|   | <b>Name</b>                  | <b>Execution Date</b> |
|   | INTELLISYN PHARMA INC.       | 08/22/2016            |
| <b>RECEIVING PARTY DATA</b>   |                              |                       |
| <b>Name:</b>  | NEOMED INSTITUTE             |                       |
| <b>Street Address:</b>  | 7171 FREDERICK BANTING       |                       |
| <b>City:</b>  | MONTREAL, QUEBEC             |                       |
| <b>State/Country:</b>   | CANADA                       |                       |
| <b>Postal Code:</b>   | H4S 1Z9                      |                       |
| <b>PROPERTY NUMBERS Total: 1</b>  |                              |                       |
|   | <b>Property Type</b>         | <b>Number</b>         |
|   | Application Number:          | 15751789              |
| <b>CORRESPONDENCE DATA</b>  |                              |                       |
| <b>Fax Number:</b>  | (919)998-5701                |                       |
| <i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i> |                              |                       |
| <b>Phone:</b>   | 919-998-5700                 |                       |
| <b>Email:</b>   | rkerney@brinksgilson.com     |                       |
| <b>Correspondent Name:</b>  | BRINKS GILSON & LIONE        |                       |
| <b>Address Line 1:</b>  | 4721 EMPEROR BOULEVARD       |                       |
| <b>Address Line 2:</b>  | SUITE 220                    |                       |
| <b>Address Line 4:</b>  | DURHAM, NORTH CAROLINA 27703 |                       |
| <b>ATTORNEY DOCKET NUMBER:</b>  | 16317-4                      |                       |
| <b>NAME OF SUBMITTER:</b>   | JENNIFER L. FOX              |                       |
| <b>SIGNATURE:</b>   | /Jennifer L Fox 52218/       |                       |
| <b>DATE SIGNED:</b>   | 07/27/2018                   |                       |
| <b>Total Attachments: 3</b>   |                              |                       |
| source=16317-4 Assignment (Intellisyn to Neomed)#page1.tif  |                              |                       |
| source=16317-4 Assignment (Intellisyn to Neomed)#page2.tif  |                              |                       |
| source=16317-4 Assignment (Intellisyn to Neomed)#page3.tif  |                              |                       |

**ROBIC, MONTRÉAL, CANADA**

**USA-CANADA-WORLDWIDE**

**ASSIGNMENT**

The undersigned:

**INTELLISYN PHARMA INC.  
(formerly known as "ERDC – EPIGENETIX R&D CENTER INC.")**

whose full postal addresses are (address is):

**7171 Frederick Banting, Montreal (Quebec) H4S 1Z9, CANADA**

in consideration of good and valuable considerations the receipt of which is acknowledged and release is given in favour of:

**NEOMED INSTITUTE**

(hereinafter referred to as the assignee)

whose full postal address is:

**7171 Frederick Banting, Montreal (Quebec) H4S 1Z9, CANADA**

do hereby sell, assign and/or transfer and/or confirm such sale, assignment and/or transfer to the said assignee all our (my) right, title and interest in the United States, Canada and everywhere else throughout the world, in and to the invention entitled:

**N-SUBSTITUTED BICYCLIC LACTAMS, THEIR PREPARATION AND THEIR USE AS  
PHARMACEUTICALS**

as fully described and/or claimed:

- in the U.S. provisional application for a patent which was filed on

**August 11, 2015**

under serial number

**62/203,588**

- in the International PCT application for a patent which was filed on

**August 11, 2016**

under serial number

**PCT/CA2016/050941**

and to all our (my) corresponding rights, titles and interests in and to any patent which may issue therefore in the United States, Canada or elsewhere throughout the world.

We (I) further agree to execute all the Forms and papers that may be necessary to file other applications in the United States, Canada and everywhere else throughout the world, on the above invention or any invention described in said application(s) and/or patent(s), in the name of the Assignee.

ROBIC : 015427-0120

**PATENT  
REEL: 046489 FRAME: 0415**

We (I) also agree to communicate to the Assignee or his representatives any facts known to us (me) respecting said invention, make all rightful oaths and generally do everything possible to aid said Assignee, its (his) successors and assignees, to obtain and enforce proper protection for said invention in the United States, Canada and everywhere else throughout the world.

The undersigned hereby grant(s) the firm of ROBIC, 1001, Victoria Square - Bloc E - 8<sup>th</sup> Floor, Montreal, Quebec, CANADA, H2Z 2B7, the power to insert further identification such as the execution date, or the application number of the application when known.

This assignment shall be governed by and construed in accordance with the applicable laws of the Province of Quebec and Canada applicable therein.

The remainder of this page has been intentionally left blank.

Signatures on the following page.

SIGNED at Montreal Quebec Canada  
 (City) (Province) (Country)

This 22<sup>nd</sup> day of August 2016  
 (day) (month) (year)

WITNESS By: **INTELLISYN PHARMA INC.**

Signature: [Signature]  
 Full name: DONNA MORLEY

Signature: [Signature]  
 Name: Jeffrey Albert  
 Title: Director

**READ AND APPROVED**

SIGNED at Montreal Quebec Canada  
 (City) (Province) (Country)

This 30 day of AUGUST 2016  
 (day) (month) (year)

By: **NEOMED INSTITUTE**

Signature: [Signature]  
 Name: MAX FEHLMANN  
 Title: PRESIDENT + CEO

ROBIC : 015427-0120